Akston Begins Trials For Room Temperature Covid Shot As Next-Generation Vaccine Race Heats Up

Massachusetts-based Akston Biosciences dosed the first participants in a Phase 2/3 study to test its Covid-19 vaccine, which is stable for at least six months at room temperature.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive